Furthermore, EPHX2 inhibition reduces inflammation in an experimental inflammatory bowel disease [79], increases the survival rate of mice after lipopolysaccharide-induced acute systemic inflammation [80], delays onset of nephritis, and ameliorates kidney damage in experimental model of lupus [81], and reduces renal inflammation and keratopathy in diabetic mice [82,83]. Here, EPHX2 is linked to inflammation.